Table 1: Summary of literature found describing the relationship between ceftaroline use and neutropenia.
|
Authors |
Year |
Study Design |
Population |
Exposure |
Neutropenia Development n (%) |
Time to Neutropenia |
Time to Normal ANC |
|
Turner, et al. |
2017 |
Retrospective multi-center cohort study |
Adult patients admitted to a 6-hospital health system in Portland, Oregon from 2011-2017 (n = 753) |
Ceftaroline therapy for ≥ 14 days |
36 (4.8%) |
Mean 20 days (25th-75th percentile, 15-29) |
Mean 3 days (range 2-23)b |
|
Jain, et al. |
2014 |
Retrospective multi-center chart review |
Adult patients at University of Washington and Harborview Medical Centers from 2011 to 2012 (n = 12) |
600 mg IV ceftaroline every 8 or 12 hours |
4 (33%) |
Mean 31 days. (Range 22-40)c |
- |
|
Furtek, et al. |
2016 |
Retrospective multi-center chart review |
Adult patients from Massachusetts General Hospital and Brigham and Women’s Hospital from 2010 to 2015 (n = 67) |
Ceftaroline therapy for ≥ 7 days |
7 (10%) |
Mean 29 days (range 13-64) |
Mean 9 days (range 3-14) |
|
Zasowski, et al. |
2017 |
Retrospective multi-center chart review |
Adult patients from 2011-2015 at Detroit Medical Center, UF Health-Shands Hospital, or Henry Ford Hospital (n = 211) |
Ceftaroline treatment |
3 (1.4%) |
Mean 16 days (range 13-20) |
- |
|
Lavie, et al. |
2016 |
Retrospective single-center chart review |
Adult patients admitted to an 800-bed academic medical center from 2012 to 2014 (n = 39) |
Ceftaroline therapy for ≥ 7 days |
7 (18%) |
Median first neutropenic day was day 17 |
Within 1 month |
|
Jansen, et al. |
2017 |
Retrospective single-center chart-review |
Patients at VA St. Louis Health Care System (n = 75) |
At least one dose of ceftaroline from 2010-2017 |
3 (4%) |
Mean 40 days (range 37-42) |
- |
|
Rimawi, et al. |
2013 |
Case Study |
90-year-old female (n = 1) |
600 mg IV ceftaroline every 12 hours |
1 (100%) |
25 days |
1 week |
|
Yam, et al. |
2014 |
Case Study |
67-year-old Caucasian man (n = 1) |
600 mg IV ceftaroline every 8 hours |
1 (100%) |
3 weeks |
9 days
|
|
a) In patients developing neutropenia b) In those with consecutive days of neutropenia (19 out of 36 patients) c) Time to discontinuation due to development of neutropenia |
|||||||